The effectiveness of perindopril in patients with isolated arterial hypertension

Objective: to assess the clinical effectiveness of perindopril in patients with isolated arterial hypertension (AH) by analyzing the dynamics of blood pressure, biochemical parameters, markers of cardiovascular risk and structural and functional state of the heart.

Object and methods of the study. 49 patients with isolated AH were examined, who were prescribed perindopril at a dose of 2–8 mg/day for 12 months. The dynamics of hemodynamic parameters, lipid metabolism indicators, kidney function (creatinine, cystatin C, glomerular filtration rate, NGAL), cardiac stress markers (NT-proBNP, cardiotrophin-1), as well as echocardiography results were assessed. Statistical analysis was performed using paired t-test and Wilcoxon criterion.

Results. A significant decrease in systolic and diastolic blood pressure, improvement in lipid profile, decrease in NT-proBNP, cardiotrophin-1, cystatin C, NGAL levels and improvement in renal function were detected. Echocardiography showed regression of the atrial, right ventricular and left ventricular end-systolic dimensions. Other parameters remained stable.

Conclusion. Perindopril effectively reduces blood pressure, improves the cardiometabolic profile and structural parameters of the heart, which confirms its feasibility in the treatment of isolated AH.

References

1. Citoni B., Figliuzzi I., Presta V. et al. (2022) Prevalence and clinical characteristics of isolated systolic hypertension in young: analysis of 24 h ambulatory blood pressure monitoring database. J. Hum. Hypertens., 36(1): 40–50. doi: 10.1038/s41371-021-00493-9.
2. Sierra C. (2017) La hipertensión arterial en el anciano [Hypertension in older adults]. Hipertens Riesgo Vasc., 34 Suppl. 2: 26–29. doi: 10.1016/S1889-1837(18)30072-2.
3. Williams B., Mancia G., Spiering W. et al. (2018) ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J., 39(33): 3021–3104. doi: 10.1093/eurheartj/ehy339.
4. Visseren F.L.J., Mach F., Smulders Y.M. et al. (2021) ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J., 42(34): 3227–3337. doi: 10.1093/eurheartj/ehab484.
5. Miotto D.S., Duchatsch F., Macedo A.G. et al. (2021) Perindopril Reduces Arterial Pressure and Does Not Inhibit Exercise-Induced Angiogenesis in Spontaneously Hypertensive Rats. J. Cardiovasc. Pharmacol., 77(4): 519–528. doi: 10.1097/FJC.0000000000000977.
6. Lee S.H., Lee C.J., Kang Y. et al. (2023) A randomized trial of genotype-guided perindopril use. J. Hypertens., 41(11): 1768–1774. doi: 10.1097/HJH.0000000000003536.
7. Kidney Disease: Improving Global Outcomes (KDIGO) (2021) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int., 99(3S): S1–S87. doi: 10.1016/j.kint.2020.11.003.
8. Böhm M., Schumacher H., Teo K.K. et al. (2017) Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet, 389(10085): 2226–2237. doi: 10.1016/S0140-6736(17)30754-7.
9. Lin B.Y., Li P., Wu X.D. et al. (2020) The Relationship Between Homocysteine, Blood Pressure Variability, and Left Ventricular Hypertrophy in Patients with Essential Hypertension: An Observational Study. Adv. Ther., 37(1): 381–389. doi: 10.1007/s12325-019-01154-7.
10. Palatini P., Kollias A., Saladini F. et al. (2024) Assessment and management of exaggerated blood pressure response to standing and orthostatic hypertension: consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J. Hypertens., 42(6): 939–947. doi: 10.1097/HJH.0000000000003704.